Houston innovator aims to connect the dots between data science and phenomena

eyes to the sky

Houstonian Joe Schurman's latest venture PhenomAInon is aimed at tapping into AI and data analytics for for space domain awareness and threat detection. Photo via Getty Images

As artificial intelligence continues to expand its sphere of influence, Spring-based expert Joe Schurman is looking to take this technology to an out-of-this-world space.

With his background includes working with advising defense and aerospace organizations like NASA, Schurman's latest venture PhenomAInon is perfectly aligned with what he’s been working towards since 2019. The company aims to be a multi-tiered subscription service and application that will be the world’s first cloud native data and AI platform for phenomenon-based data analysis that can analyze data from any source for space domain awareness and threat detection, according to Schurman.

The platform aims to provide end-to-end data and AI analysis, publish insights, build community, and provide cloud, data, and software consulting. PhenomAInon deploys data and AI services alongside modern data and AI engineering, per the website, to surface insights to explorers, researchers, organizations, publications, and communities through advanced data and AI analysis. Schurman has worked with the U.S. government's task force for unidentified anomalous phenomenon — any perceived aerial phenomenon that cannot be immediately identified or explained — known as UAPTF. The tool will run sensitive information and then get back custom video analysis. The public version of the tool will give the public the option to view videos and cases, and form their own analysis.

“We are working together with multiple teams both public and private to continue to curate the data sets, clear documents for public review, and provide advanced analytics and AI capabilities never seen before to the public,” Schurman tells InnovationMap. “From a data and analytics perspective, we are applying machine learning and advanced analytics to find correlations and anomalies in the incident reports across multiple data sets.

"Some of these are public, some are private, and some we are clearing for public review," he continues. "The analytics will go far beyond incident reporting and showcase heat maps, correlative incident maps to key private and public sector facilities, and trends analysis never reported — e.g. incident reporting correlated with time, weather, FAA, and drone flight data, etc. We also have a new content analysis platform where users will be able to eventually run their own AI and ML analysis on their own videos.”

Schurman was first able to show this to the world in 2019, when as an adviser for To The Stars Academy of Arts and Science, or TTSA. He also appeared on History Channel’s “Unidentified: Inside America's UFO Investigation” to show the Pentagon’s former Advanced Aerospace Threat Identification Program head and TTSA Director of Special Programs Luis Elizondo how the AI platform could be helpful in tracking data related to Unidentified Aerial Phenomena.

Now, PhenomAInon's app is a work-in-progress. While it soft launched in May of 2022, Schurman says they have several data sets that are awaiting clearing from the U.S. government, as well as the content analysis tool in development to launch possibly by the summer. Schurman also hopes they will curate the largest library of incident videos, images, and audio recordings.

The subject of UAP continues to attract new discussions from government officials and industry professions across aerospace, academia, and more. In Houston, Rice University's Woodson Research Center and its humanities department host one of the largest archives of UAP and paranormal data, notes, and research that include documents from CIA programs on remote viewing.

Schurman says he's looking to provide even more data and information in this space.

“This phenomenon, it’s implications to multiple aspects of our lives and possible security threats, all come down to a data problem and the organizations that have been in place to-date just have not had the level of cloud, data and AI engineering capabilities we take for granted and have access to in the private sector,” says Schurman. “My goal is to bring this all together, starting with PhenomAInon.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings